Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56,078,244
-
Total 13F shares
-
20,059,301
-
Share change
-
-80,889
-
Total reported value
-
$55,595,531
-
Price per share
-
$2.77
-
Number of holders
-
63
-
Value change
-
-$1,845,680
-
Number of buys
-
27
-
Number of sells
-
39
Institutional Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q1 2022
As of 31 Mar 2022,
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) was held by
63 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,059,301 shares.
The largest 10 holders included
NEA Management Company, LLC, Bellevue Group AG, RA CAPITAL MANAGEMENT, L.P., BOXER CAPITAL, LLC, Artal Group S.A., FEDERATED HERMES, INC., VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, TWO SIGMA INVESTMENTS, LP, and STATE STREET CORP.
This page lists
64
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.